Stoke Therapeutics
STOK
96 hedge funds and large institutions have $372M invested in Stoke Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 16 closing their positions.
757% more call options, than puts
Call options by funds: $120K | Put options by funds: $14K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1% more capital invested
Capital invested by funds: $369M → $372M (+$2.68M)
0.56% less ownership
Funds ownership: 101.43% → 100.86% (-0.56%)
9% less funds holding
Funds holding: 106 → 96 (-10)
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$31.6M |
| 2 |
CAC
Cowen and Company
New York
|
+$22.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$9.08M |
| 4 |
RI
RTW Investments
New York
|
+$4.69M |
| 5 |
Morgan Stanley
New York
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.62M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$5.21M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.24M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.96M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.71M |
STOK Hedge Fund Activity: Q1 2023 in Review
96 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2023, worth a combined $372M — up 0.73% from $369M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of STOK and 6 opened new positions — a net loss of 10 holders — while 40 trimmed existing stakes and 33 added.
The largest buyer was Redmile Group, adding an estimated $31.6M. The largest seller was Fidelity Investments, cutting an estimated $9.62M.
- 96 institutional investors held Stoke Therapeutics (STOK) as of Q1 2023, down from 106 in Q4 2022.
- Funds reported $372M of Stoke Therapeutics stock for Q1 2023, up 0.73% quarter-over-quarter.
- 6 funds opened new Stoke Therapeutics positions in Q1 2023 and 16 closed out, a net change of -10 holders.
- The largest Stoke Therapeutics buyer in Q1 2023 was Redmile Group, an estimated $31.6M added.
- The largest Stoke Therapeutics seller in Q1 2023 was Fidelity Investments, an estimated $9.62M sold.
Based on aggregated 13F filings for Q1 2023.